{"entity":{"id":"uwe-platzbecker","kind":"person","name":"Uwe Platzbecker","aka":[],"tldr":"Led MEDALIST and COMMANDS, which made luspatercept a first-line treatment for anaemia in lower-risk MDS.","summary":"Uwe Platzbecker (Leipzig) was a principal investigator of MEDALIST and led COMMANDS, the trials establishing luspatercept for transfusion-dependent anaemia in lower-risk myelodysplastic syndromes, first after and then instead of erythropoiesis-stimulating agents. He coordinates the German MDS Study Group and the European MDS registry and has led trials of hypomethylating agent combinations in higher-risk disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Platzbecker%20U%5BAuthor%5D%20luspatercept%20MDS"}],"tags":["mds","anaemia","trialist"],"related":[],"cancers":["mds","aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["university-hospital-leipzig"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-commands-luspatercept-mds-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital Leipzig","institutionId":"university-hospital-leipzig","specialisms":["Myelodysplastic syndromes","Anaemia therapeutics","Acute myeloid leukaemia","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Platzbecker%20U%5BAuthor%5D%20luspatercept%20MDS"}],"papers":[{"title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00874-7"},{"title":"Luspatercept in patients with lower-risk myelodysplastic syndromes (MEDALIST)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa1908892"},{"title":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=COMMANDS%20luspatercept%20epoetin%20alfa%20lower-risk%20MDS%20Platzbecker%20Lancet%202023"}]},"route":"/people/uwe-platzbecker/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"institution":[{"id":"university-hospital-leipzig","kind":"institution","name":"Leipzig University Hospital / University Cancer Center Leipzig (UCCL)","route":"/institutions/university-hospital-leipzig/"}],"paper":[{"id":"paper-commands-luspatercept-mds-lancet-2023","kind":"paper","name":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","route":"/key-papers/paper-commands-luspatercept-mds-lancet-2023/"}],"trial":[{"id":"commands","kind":"trial","name":"COMMANDS","route":"/trials/commands/"},{"id":"imerge","kind":"trial","name":"IMerge","route":"/trials/imerge/"}]}}